ARTICLE | Company News
Shenogen, Lee's forge another cancer combo deal
December 1, 2017 12:03 AM UTC
Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) and Shenogen Pharma Group Ltd. (Beijing, China) partnered to jointly develop and commercialize a combination therapy in China to treat late-stage cancers. The therapy will comprise Lee's ZKAB001, which is a mAb against PD-L1, and Shenogen's icaritin (SNG-162), a small molecule derived from a Chinese herb targeting estrogen receptor alpha 36.
The partners expect synergistic effects from the combo based on animal studies...
BCIQ Target Profiles